Add this topic to your myFT Digest for news straight to your inbox
Treatment is new weapon against mosquito-borne disease that kills 20,000 people a year
Men in their 30s with no underlying health conditions died three days after second shot
The sale of subsidiary will help the Japanese pharmaceutical to bring down leverage
A successful coronavirus treatment may not lead to blockbuster sales
Industry highlights bottlenecks in access to materials that are a possible Covid-19 treatment
Japanese drugmaker is looking to reduce its $48bn debt following Shire acquisition
Japanese pharmaceutical group eyes reduction in $48bn debt pile following acquisition
If gene therapy lives up to its promise, it will justify the song and dance
Vote paves way for Japan’s largest ever corporate takeover
The FT's Daniel Garrahan previews some of the big stories in the week ahead
Takeda could be just the first of many looking for growth through acquisitions abroad
Former chair and member of founding family of Japanese drugmaker opposes acquisition
Unhappy shareholders are right to resist the purchase of Shire
Bankers, lawyers and PR advisers to receive huge payday for Japan’s largest overseas takeover
Closely watched meeting comes as some shareholders step up campaign to derail deal
Fears over sales of Velcade support case for £46bn deal to buy Shire
Japanese drugmaker awaits antitrust decisions in Japan, Europe and China
Investor group had sought to derail Japanese drugmaker’s £46bn takeover of Shire
Christophe Weber ‘very comfortable’ with durability of lucrative haemophilia franchise
International Edition